AFPZydus Cadila on Thursday said it has applied for emergency use approval (EUA) for its 3-dose Covid-19 vaccine that showed 66.6% efficacy in an interim study.
The Ahmedabad-based drug maker has not stockpiled any doses yet, but hopes to produce 10 million doses by mid-August and 50 million doses by December, its managing director Sharvil Patel said.
"We are currently in a scale up phase. We have not stockpiled because our new plant is coming up," he said.
At present, the company is trying to produce 4-5 lakh doses per month, Patel said. "But as soon as the new facility starts running, we believe we can produce one crore doses monthly. We believe we can start from mid-August to have a run rate of one crore doses per month. If everything goes well, we will produce five corre doses by December."
Subject expert committee (SEC) of the Central Drugs Standards Control Organisation is expected to take up the Zydus vaccine for review this week.
If it gets the nod, it would be the fifth vaccine to be introduced in India.
The Ahmedabad-based drug maker has not stockpiled any doses yet, but hopes to produce 10 million doses by mid-August and 50 million doses by December, its managing director Sharvil Patel said.
"We are currently in a scale up phase. We have not stockpiled because our new plant is coming up," he said.
At present, the company is trying to produce 4-5 lakh doses per month, Patel said. "But as soon as the new facility starts running, we believe we can produce one crore doses monthly. We believe we can start from mid-August to have a run rate of one crore doses per month. If everything goes well, we will produce five corre doses by December."
Subject expert committee (SEC) of the Central Drugs Standards Control Organisation is expected to take up the Zydus vaccine for review this week.
If it gets the nod, it would be the fifth vaccine to be introduced in India.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.